Second call for retraction of a fraudulent trial report of fluoxetine in children and adolescents
We wrote to JAMA Psychiatry on 3 August calling for retraction of a fraudulent trial report of fluoxetine in children and adolescents. Read our open letter here. On 21 September, Anette Flanagin, Executive Managing Editor, Vice President, Editorial Operations JAMA and JAMA Network, sent a misleading response: We shared your letter with the author of […]